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Abstract
Human prion diseases constitute a group of infectious and invariably fatal neurodegenerative disorders associated
with misfolding of the prion protein. Variant Creutzfeldt–Jakob disease (vCJD) is a zoonotic prion disease linked to
oral exposure to the infectious agent that causes bovine spongiform encephalopathy (BSE) in cattle. The most
recent case of definite vCJD was heterozygous (MV) at polymorphic codon 129 of the prion protein gene PRNP
while all of the previous 177 definite or probable vCJD cases who underwent genetic analysis were methionine
homozygous (MM). Retrospective prevalence studies conducted on lympho-reticular tissue suggest that the number
of asymptomatic vCJD carriers in the United Kingdom might be around 1 in 2000 people. In addition, there have
been four known cases of the transmission of vCJD infection via blood transfusion. For these reasons, a sensitive,
reliable, and fast diagnostic test is currently needed. We describe a rapid and highly sensitive seeding conversion
assay that detects disease-associated prion protein in the brain and cerebrospinal fluid in vCJD after 48–96 h of
amplification, with 100% sensitivity and specificity. This method can amplify prions from definite, probable, and
possible vCJD cases from patients who are either MM or MV at PRNP-codon 129.
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Introduction
Human prion diseases constitute a group of fatal neuro-
logical disorders classified according to their clinical,
genetic, and neuropathological features as sporadic,
familial, or acquired [1]. A common feature of human
prion diseases is the conformational change of a normal
endogenous protein, the prion protein (PrPC), to the
misfolded and disease-associated form PrPSc, which
accumulates in central nervous system tissue [2]. Cur-
rently, variant Creutzfeldt-Jakob disease (vCJD) in
humans is considered the only zoonotic human prion
disease, with evidence suggesting that it is caused by
oral exposure to the infectious agent associated with
bovine spongiform encephalopathy (BSE) that affected
cattle in the United Kingdom and Europe [3]. Although
PrPSc accumulation occurs primarily in the brain in
human prion disease, a notable feature of vCJD is the
detection of PrPSc in the lymphoid tissues including
spleen, tonsil, and appendix [2,4]. Retrospective preva-
lence studies, based on the analysis of anonymized
appendectomy samples for the presence of PrPSc, esti-
mate that the number of asymptomatic carriers in the
United Kingdom may be around 1 in 2000 people,
which differs significantly from the number of clini-
cally reported cases [4]. This raises important concerns
about the potential for further secondary transmission
of vCJD and underscores the need for a sensitive, reli-
able, and fast diagnostic test.
With this aim, we have established an optimized
assay to detect prions from suspected CJD cases in
life, based on the in vitro amplification method Pro-
tein Misfolding Cyclic Amplification or PMCA.
Materials and methods
Biological samples
Cerebrospinal fluid samples
Cerebrospinal fluid (CSF) samples are sent to the
laboratory on dry ice and stored at 2808C prior to
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analysis. For this study CSF 14-3-3, tau protein and
phosphorylated tau were analysed (For additional
details, see supplementary materials and methods).
Consent for research was obtained for each sample
and ethical approval was given by the MREC Scot-
land A (05/MRE00/67).
vCJD and sCJD brain tissues
Human brain tissue was obtained from the MRC Edin-
burgh Brain Bank. The specimens (frontal cortex) were
sampled from a frozen half brain with the appropriate
consent for research use (East of Scotland Research
Ethics service REC 1, reference number 16/ES/0084).
Amplification procedure (PMCA/hsPMCA),
proteolytic treatment, Western blotting, and
criteria for positivity
All procedures were performed in a category 3*
(*with derogation) containment laboratory with
strict adherence to health and safety protocols. The
preparation of normal brain homogenate, human
brain derived vCJD seed, preparation of amplifica-
tion mixture, and amplification procedure are given
in supplementary materials and methods. Details of
the proteolytic treatment, western blotting, and crite-
ria for positivity [5,6] are also provided in supple-
mentary materials and methods.
Statistical analysis
Estimated sensitivity and specificity and 95% confi-
dence intervals were calculated using MedCalc ver-
sion 17.6.
Blinded samples
CSF samples were provided as a blinded panel. They
were decoded after the amplification analysis was
performed and the experimental outcome evaluated.
Results and discussion
Based on the molecular susceptibility of PrPC by the
abnormal and misfolded isoform PrPSc, the in vitro
conversion systems such as Protein Misfolding Cyclic
Amplification (PMCA) and Real-Time Quaking
Induced Conversion (RT-QuIC) have provided impor-
tant advances in the development of diagnostic
opportunities for several protein misfolding disorders
including human prion diseases [7–15].
Prior to optimization [5,6], our standard PMCA
protocol used transgenic mouse brain homogenate
expressing the human PRNP gene homozygous for
methionine at codon 129, as a substrate source of
normal PrPC for conversion (supplementary mate-
rial, Figure S1A) [16]. This substrate was seeded
with vCJD prions. After proteolytic treatment
(Proteinase K) and western blotting, the protease
resistant core of PrPSc (PrPres) was immunode-
tected using the monoclonal antibody 3F4. Using
a single 48 h round of standard PMCA, amplified
PrPSc was detected after an initial dilution of vCJD
brain seed in substrate of 1 3 1026 – 1 3 1027
(supplementary material, Figure S1B). This level of
sensitivity for a single round of PMCA is equi-
valent to that reported by others leading groups
[8,10,17].
Detection of vCJD prions in human biological flu-
ids such as whole blood, plasma, and urine demands
high sensitivity of the PMCA, achieved partially by
extensive rounds of in vitro amplification, causing
delay in the reporting and involving laborious manip-
ulation. By using serial rounds of amplification,
vCJD prions have recently been detected in buffy
coat, complete blood and plasma from vCJD patients
after 2–4 rounds of PMCA [8,10,17]. PrPSc was also
identified in urine samples of vCJD patients after
extensive amplification [13]. However, the potential
risk of cross-contamination of samples due to the
experimental handling is a concern when clinical
samples need to be examined using prolonged experi-
mental practices.
Here we report a highly sensitive PMCA proce-
dure (hsPMCA) to detect minute quantities of vCJD
prions within a relatively short-time period requiring
minimal manipulation of the human clinical
samples.
This method is able to readily detect vCJD prions
diluted 100 billion-fold (1 3 10211) from the brain
homogenate of a definite case of vCJD after a single
round of amplification (supplementary material, Fig-
ure S2A). The sensitivity of hsPMCA showed a mini-
mum of five-fold increase when compared to
standard PMCA (supplementary material, Figure S1B
and S2B). The hsPMCA uses the combination of
heparin (previously utilized with cellular substrates
[15,18]) and transgenic substrate [5,6], and the incor-
poration of beads [8,10,13,17,19] as in vitro amplifi-
cation enhancers. The effect of heparin and Teflon
beads on the highly efficient conversion of CJD
prions, but in particular of vCJD prions, may suggest
direct interactions among the seed, substrate, and
these two other hsPMCA components. The glycos-
aminoglycan heparin for example has been shown to
bind to the normal and abnormal forms of the prion
protein during the amplification of mouse-adapted
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strains [18]. Future studies are needed to clarify the
nature of the in vitro interaction between human CJD
prions and the amplification promoters, and its possi-
ble pathophysiological relevance. However, it would
appear from our data that it is the incorporation of
Teflon beads combined with the effect of heparin
that may contribute to the high sensitivity reached by
hsPMCA.
In view of the sensitivity of the hsPMCA assay for
the detection of vCJD prions, we carried out a small
pilot study, in which blinded CSF samples from two
vCJD patients (one definite and one probable case),
one sporadic CJD (sCJD) patient, and one other-
neurodegenerative disease (other-ND) case were ana-
lysed by hsPMCA. After a single round of amplifica-
tion, the two vCJD samples showed PrPres. No
amplified product was detected for either the sCJD
or the negative control samples (Figure 1A). To
estimate the optimal volume of CSF required for
amplification of vCJD prions, we further analysed a
range of CSF volumes from these samples. Using the
hsPMCA method, PrPres was detected from a 2.5 ml
volume of CSF from the definite case of vCJD. The
probable case of vCJD required a higher volume
(around 7 ml) of CSF (seed) to propagate prion
in vitro after one round of amplification (Figure 1B).
In reactions seeded with 10 and 16.8 ml CSF from the
case of definite vCJD, no amplified PrPres was detected,
suggesting that higher concentrations of CSF compo-
nents may have inhibited amplification (Figure 1B).
The failure of the sCJD MM1 CSF, and the low
amplification of MM1 and MV2K brain samples to
seed detectable PrPres after hsPMCA, suggests that
our methodology is not yet optimized for the detec-
tion of sCJD prions (supplementary material, Figures
S2B and S2C). However, other in vitro amplification
Figure 1. Detection of vCJD prions in cerebrospinal fluid samples by hsPMCA. (A) CSF samples from one probable and one definite
vCJD (vCJD1 and vCJD2, respectively), one sporadic CJD MM1 (sCJD1), one non-CJD neurodegenerative disease case (Other-ND), one
non-neurodegenerative case (non-ND), and two reactions incubated with PBS were evaluated by hsPMCA. Reactions were seeded
with a final volume of 8.4 ml of sample. Non-amplified frozen (‘F’) and amplified (‘S’) samples were analysed. (B) A range of CSF sam-
ple volumes were considered for amplification using the same CSF panel. The samples were mixed with an equal volume of substrate
(83.2 ml) and normalized to a final 100 ml reaction volume. The samples were subjected to a single round of amplification. Samples
were treated with Proteinase K and evaluated by western blotting using 3F4 mAb. Reference molecular mass of electrophoretic
markers is shown. (*) Incomplete proteolytic digestion of PrP. [N5 5; 2 vCJD (definite and probable), 1 sCJD, 1 non-ND, 1 Other-ND].
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assays possess the levels of sensitivity and specificity
to detect sCJD prions in CSF and in other clinical
specimens [11,12,20].
Following on from the pilot study, we analysed a
larger blinded panel of CSF samples comprising 10
definite vCJD cases, 6 sCJD MM1 cases, and 10 CSF
samples from other neurodegenerative diseases, non-
neurodegenerative disease (non-ND) and non-CJD
controls (Figure 2A, and Table 1). An additional group
of 23 CSF samples from other-ND/non-ND/non-CJD
controls were also tested (Figure 3). In this analysis,
7.5 ml of CSF sample were included directly in the
amplification mixture without any pre-treatment of the
CSF sample. After a single 48 h round of PMCA, six of
the ten vCJD samples showed PrPres by western blot-
ting. The remaining four vCJD CSF samples showed
robust amplification after a second round. In contrast,
none of the sCJD MM1 or the negative controls
showed any evidence of PrPres formation after a single
or second round of amplification (Figure 2A).
Figure 2. Detection of vCJD prions in CSF samples in a larger blinded panel of PRNP-codon 129MM and MV cases by hsPMCA. (A) A
second blinded panel of CSF samples were evaluated including 10 definite vCJD codon 129MM (vCJD 3–12), 6 sCJD MM1 (sCJD 1–6),
and 10 CSF controls from other neurodegenerative diseases (Other–ND), non-CJD (non-CJD), and non-neurodegenerative diseases
(non-ND). A volume of 7.5 ll of CSF (for each sample) was mixed with 92.5 ll volumes of substrate and subjected to amplification.
(B) Analysis of two vCJD PRNP-codon 129MM cases, one possible (vCJD 14) and one probable (vCJD 15), a definite vCJD codon
129MV case reported recently in the United Kingdom (vCJD 13), and one non-neurodegenerative (non-ND) control were evaluated by
hsPMCA. Two amplification rounds were completed (Round 1 and 2). Samples were treated with Proteinase K and evaluated by West-
ern blotting using 3F4 mAb. The molecular mass of electrophoretic markers (MM) is shown. [N5 30; 13 vCJD (definite, possible and
probable), 6 sCJD, 5 non-ND, 6 Other-ND].
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As a further test of the hsPMCA CSF assay, the
second CSF blinded panel, also contained one possi-
ble and one probable vCJD codon 129MM case, and
a third sample from the first definite codon 129MV
vCJD case reported in the United Kingdom [21]. The
possible and probable codon 129MM cases were able
to seed the hsPMCA producing detectable levels of
PrPres after one round of amplification. Moreover, the
CSF sample derived from the vCJD codon 129MV
case showed readily detectable levels of PrPres after
the second round of amplification (Figure 2B).
This study demonstrates for the first time that CSF
samples from possible, probable, and definite cases of
vCJD are able to propagate in vitro. The hsPMCA was
able to support conversion of vCJD prions from codon
129MM and MV patients. Considering the number of
samples analysed, we report an estimated sensitivity of
100% (95% CI, 69.15–100.00) and a specificity of
100% (95% CI, 89.42–100.00) of the hsPMCA assay
within a 48–96 h period and with minimal manipula-
tion of the clinical specimens. Currently, 178 cases of
vCJD have been reported in the United Kingdom. It is
also estimated that 1 in 2000 people are unidentified
asymptomatic carriers. This study evaluates for the first
time the presence of the vCJD prions in CSF samples
of 15 symptomatic vCJD cases who are either MM or
MV at PRNP-codon 129, 6 sCJD, and 35 controls (sup-
plementary material, Table S1). The relatively small
absolute number of vCJD cases included in the study
represents around 8.4% of the total number cases
reported in the United Kingdom, not all of which have
Table 1. CJD and non-CJD cases evaluated for vCJD prions by
hsPMCA
Diagnosis
Detection
of vCJD prions
by hsPMCA
vCJD
Definite 11 (codon 129MM) 11/11
1 (codon 129MV) 1/1
Possible 1 (codon 129MM) 1/1
Probable 2 (codon 129MM) 2/2
15/15
sCJD
Definite 5 (codon 129MM) 0/5
Probable 1 (codon 129MM) 0/1
0/6
Other neurodegenerative
diseases*
21 0/21
Non-neurodegenerative
diseases and improved cases†
14 0/14
*The ‘other neurodegenerative diseases’ group comprised cases of: Alzhei-
mer’s disease, Lewy body disease, Frontotemporal dementia, Cortical/strial/
nigral degenerative disorder, Epinocerebellar ataxia, Paraneoplastic syndrome,
Voltage gated K channelopathy, and Neuroaxonal dystrophy.
†The ‘other non-neurodegenerative diseases and improved cases’ group com-
prise cases of: Diffuse large B cell lymphoma, Carcinomatosis of leptomenin-
ges and brain, Progressive multifocal leukoencephalopathy, Angiotrophic
lymphoma, Cerebrovascular disease, Small brain-stem haemorrhages, Normal
pressure hydrocephalus, and Intravascular B cell lymphoma.
Figure 3. Analysis of vCJD prions in CSF samples versus non-CJD controls by hsPMCA. Twenty three CSF samples including cases of
other neurodegenerative diseases (Other–ND), non-neurodegenerative diseases (Non-ND), and non-CJD controls (non-CJD) were eval-
uated by hsPMCA for detection of vCJD prions. CSF from a definite vCJD case (vCJD2) and two unseeded reactions (PBS1-PBS2) were
included. Two rounds of amplification were performed (Round 1 and 2). The reactions were analysed for PrPres after PK treatment
and western blotting using 3F4 mAb. The molecular mass of electrophoretic markers (MM) is shown. [N5 24; 1 vCJD, 8 non-ND, 14
Other-ND, 1 non-CJD].
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available CSF. Further analysis needs to be considered
to confirm and extend the sensitivity and specificity
values reported here, in a larger cohort of symptomatic,
but also asymptomatic individuals. Direct comparison
of our hsPMCA results with other previously published
studies of CJD prions in human body fluid and tissues
is challenging and complex. The use of different ampli-
fication protocols, types and substrate origin, amplifica-
tion enhancers, sample treatment, and the use of human
blood, urine, and CSF samples analysed complicate the
comparisons and merit exhaustive review elsewhere.
However, crucially, the hsPMCA assay provides a sig-
nificant advantage in the development of a pre-mortem
diagnostic test for vCJD. Therefore, hsPMCA may be a
valuable contribution in the surveillance for vCJD and,
in combination with RT-QuIC, may facilitate the differ-
ential diagnosis of sCJD and vCJD.
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